Related Experiment Video
Updated: Aug 23, 2026

Methods to Investigate the Regulatory Role of Small RNAs and Ribosomal Occupancy of Plasmodium falciparum
Published on: December 4, 2015
Schistosome resistance to praziquantel: Fact or artifact?
P G Fallon1, L F Tao, M M Ismail
1Department of Pathology, University of Cambridge. Tennis Court Road, Cambride, UK. pgf@mole.bio.cam.uk
Abstract:
Praziquantel is the current drug of choice for human schistosomiasis. Recent reports from laboratory and field studies concerning reduced praziquantel efficacy against Schistosoma mansoni have generated some controversy. The prevailing question is whether the emergence of strains of schistosome resistant to praziquantel is a fact, or an artifact resulting from erroneous field or laboratory experimentation. In this article, Padraic Fallon, Liang-feng Tao, Magdi Ismail and James Bennett examine the available evidence for schistosome resistance to praziquantel. Contributory factors to the schistosomicidal activity of praziquantel, which may interfere with evaluation of drug efficacy or resistance, are also considered.
Related Concept Videos
Antiprotozoal Agents
Anthelminthic Agents
Malaria

